The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and Xeljanz — with prices increases that are not supported by new clinical evidence, with a total of $815 million in added costs to U.S. payers in 2023.
Beginning in January 2025, Optum Rx will remove from several Humira biosimilars from its formulary, including Hyrimoz (adalimumab-adaz), the unbranded Hyrimoz and Cyltezo (adalimumab-adbm).
The biggest advantage of suzetrigine would be that it helps patients avoid the use of opioids for acute pain. The FDA’s goal date for suzetrigine is Jan. 30, 2025.
PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs.
Patients with type 1 diabetes were more likely to be prescribed continuous glucose monitoring compared with those with type 2 diabetes, a new analysis finds.
Whether this proposed rule actually has any impact remains to be seen, especially with a new administration led by Donald Trump’s new health appointees.
CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
An intervention program that coaches patients in stress management and goal setting, along with a digital app, helped adolescents experience less distress and improved self-management behavior.
After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Mehmet Oz, M.D., is another unconventional pick by Trump and is perhaps another an indication that Trump intends to let his HHS secretary nominee, Robert F. Kennedy Jr., "go wild on health."
Monjuvi is available under an accelerated approval to treat adults with relapsed or refractory diffuse large B-cell lymphoma.
Kebilidi is a one-time gene therapy administered directly to the brain in patients with AADC deficiency, rare genetic disorder.
Almost half of those surveyed by Navitus Health Solutions said they’ve been unable to fill a needed prescription because of cost.
An FDA advisory committee last year agreed that the data do not support phenylephrine as an effective nasal decongestant.
Clinicians have very strong concerns about the cost of biologics to treat food allergies, but despite these concerns, enthusiasm in the field for their use remains very high.
In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
A clinical trial in the United Kingdom has found that Stelara may help to reduce the level of a type of immune cell, which appears to play a role in destroying insulin-producing cells.
ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Qsymia’s manufacturer also released postmarketing data showing the oral therapy for weight loss was associated with reductions in 24-hour mean systolic blood pressure.
A recent study has found that biologics may have an effect on arterial wall inflammation and plaque composition, which offsets the influence of joint-derived inflammation in patients with arthritis.
Clinical and other trials for GLP-1 therapies have found an association between these drugs and diabetic retinopathy complications in patients. But this could be an early worsening of disease unrelated to treatment.
Children with serious eye conditions are at an increased risk of developing mental health conditions, including schizophrenia, anxiety, depression and bipolar.
The CDC’s Timothy M. Uyeki, M.D., cautioned, however, that if the virus changes, and especially if it begins to infect pigs, that would be a game changer, allowing the virus to mutate to one that is more of a threat to people.
David Joyner has been appointed president and CEO of CVS Health effective immediately.
New research finds that the financial burden of treatment for age-related macular degeneration can lead to delayed or incomplete treatment and poor outcomes. Telehealth and remote monitoring could reduce gaps.
Recent outbreaks of infections related to procedures done outside the United States, such as the fungal meningitis outbreak last year related to cosmetic surgery in Mexico, demonstrate the risks of medical tourism.
The Centers for Disease Control and Prevention provides funding for HIV prevention for the populations at the highest risk of infection. State efforts to shift priorities could lead to poorer outcomes, more deaths and increased costs.
Identifying the priority populations for PrEP is crucial for guiding the future HIV prevention options, researchers said.
Interim results of a phase 2 trial indicate that the mpox vaccine MVA-VN has an immune response in adolescents similar to that of adults with no safety signals six months after the last dose.
